---
input_text: Ethical Analysis and Policy Recommendations Regarding Domino Liver Transplantation.
  Due to the widening gap between supply and demand, patients who need a liver transplant
  due to metabolic disease may be asked to serve as domino liver donors-to have their
  native liver transplanted into another candidate. We here analyze the ethical problems
  surrounding informed consent for the implant and explant procedures in transplant
  candidates who will serve as domino donors, using the case of a child with maple
  syrup urine disease. We discuss the need for 2 distinct consent processes separated
  in time to ensure that potential domino donors (or their surrogates) give a truly
  voluntary consent. We propose a Domino Donor Advocate-based on the concept of the
  independent living donor advocate to help the patient and/or his or her surrogates
  consider the risks, benefits and alternatives. Finally, we evaluate the Organ Procurement
  and Transplantation Network policy regarding "therapeutic organ donation" and propose
  several modifications to ensure that the decision by the potential domino donor
  (and/or his or her surrogate) is voluntary and informed.
raw_completion_output: |-
  primary_disease: Maple syrup urine disease
  medical_actions: Ethical analysis;Policy recommendations;Informed consent processes;Domino Donor Advocate;Evaluation of Organ Procurement and Transplantation Network policy
  symptoms: N/A
  chemicals: N/A
  action_annotation_relationships: Ethical analysis PREVENTS ethical problems IN Maple syrup urine disease;Policy recommendations PREVENTS ethical problems IN Maple syrup urine disease;Informed consent processes PREVENTS involuntary consent IN Maple syrup urine disease;Domino Donor Advocate PREVENTS involuntary consent IN Maple syrup urine disease;Evaluation of Organ Procurement and Transplantation Network policy PREVENTS involuntary consent IN Maple syrup urine disease
prompt: |+
  From the text below, extract the following entities in the following format:

  subject_extension: <A chemical or drug mentioned in the relationship between the medical action and the symptom, for example, "analgesic agent therapy" has the aspect "analgesic">
  object_extension: <An optional term describing some specific aspect of the object, e.g. "analgesic agent therapy" has the aspect "analgesic">
  subject: <The medical action. For example: blood transfusion, radiation therapy, cardiac catheterization, pulse oximetry, otoscopy>
  predicate: <The relationship type between the medical action and the symptom, usually TREATS or PREVENTS.>
  object: <A sign or symptom associated with the disease and targeted by the medical action. For example, Low serum calcitriol, hypoplasia of the thymus, chronic cough, aortic stiffness, low pulse pressure>
  qualifier: <The primary disease the relationship is about, or specifically the disease the symptom is related to. For example, Beck-Fahrner syndrome, hereditary retinoblastoma, progeria, diabetes mellitus, infectious otitis media>
  subject_qualifier: <An optional qualifier or modifier for the subject of the statement, e.g. "high dose" or "intravenously administered">
  object_qualifier: <An optional qualifier or modifier for the object of the statement, e.g. "severe" or "with additional complications">


  Text:
  Evaluation of Organ Procurement and Transplantation Network policy PREVENTS involuntary consent IN Maple syrup urine disease

  ===

extracted_object:
  primary_disease: MONDO:0009563
  medical_actions:
    - Ethical analysis
    - Policy recommendations
    - Informed consent processes
    - Domino Donor Advocate
    - Evaluation of Organ Procurement and Transplantation Network policy
  symptoms:
    - N/A
  chemicals:
    - N/A
  action_annotation_relationships:
    - subject: Ethical analysis
      predicate: PREVENTS
      object: ethical problems
      qualifier: MONDO:0009563
    - subject: Policy recommendations
      predicate: PREVENTS
      object: ethical problems
      qualifier: MONDO:0009563
    - subject: Informed consent processes
      predicate: PREVENTS
      object: involuntary consent
      qualifier: MONDO:0009563
    - subject: PREVENTS
      predicate: PREVENTS
      object: involuntary consent
      qualifier: MONDO:0009563
      subject_extension: Domino Donor Advocate
    - subject: <Evaluation of Organ Procurement and Transplantation Network policy>
      predicate: <PREVENTS>
      object: <involuntary consent>
      qualifier: <Maple syrup urine disease>
      subject_extension: <Organ Procurement and Transplantation Network policy>
      object_extension: <involuntary consent>
named_entities:
  - id: MONDO:0009563
    label: Maple syrup urine disease (MSUD)
  - id: CHEBI:25017
    label: Leucine
  - id: CHEBI:22359
    label: alloisoleucine (allo-ile)
  - id: HP:0100626
    label: End stage liver diseases
  - id: MONDO:0100193
    label: End stage liver diseases
  - id: MONDO:0019052
    label: Inborn errors of metabolism
  - id: MAXO:0000603
    label: Peritoneal dialysis
  - id: MAXO:0001175
    label: Liver transplantation (LT)
  - id: MAXO:0009003
    label: Preimplantation genetic testing (PGT)
  - id: CHEBI:24898
    label: isoleucine
  - id: CHEBI:27266
    label: valine
  - id: MAXO:0000088
    label: diet
  - id: HP:0001263
    label: mental and motor retardation
  - id: HP:0002098
    label: respiratory distress
  - id: MONDO:0008143
    label: Organic Acidemias (OAs)
  - id: MONDO:0000688
    label: Organic Acidemias
  - id: MONDO:0021055
    label: Familial amyloidotic polyneuropathy (FAP)
  - id: HP:0003159
    label: hyperoxaluria
  - id: MONDO:0002474
    label: primary hyperoxaluria
  - id: MONDO:0008294
    label: acute intermittent porphyria
  - id: HP:0011034
    label: Amyloidosis
  - id: HP:0011968
    label: Poor feeding
  - id: HP:0001259
    label: Coma
  - id: HP:0001252
    label: Hypotonia
  - id: HP:0002013
    label: vomiting
  - id: HP:0000737
    label: irritability
  - id: HP:0003256
    label: Coagulopathy
  - id: HP:0001993
    label: Ketoacidosis
  - id: HP:0001251
    label: Ataxia
  - id: MONDO:0017052
    label: intermediate maple syrup urine disease (iMSUD)
  - id: MAXO:0001525
    label: Intravenous administration
  - id: CHEBI:17895
    label: Tyr
  - id: CHEBI:16828
    label: Trp
  - id: CHEBI:141437
    label: His
  - id: CHEBI:16044
    label: Met
  - id: CHEBI:16857
    label: Thr
  - id: CHEBI:30011
    label: Gln
  - id: CHEBI:17295
    label: Phe
  - id: CHEBI:28300
    label: glutamine
  - id: CHEBI:16449
    label: alanine
  - id: CHEBI:27363
    label: zinc
  - id: CHEBI:27568
    label: selenium
  - id: CHEBI:27432
    label: alpha-linolenic acid (18:3n-3)
  - id: CHEBI:36005
    label: docosahexaenoic acid (22:6n-3)
  - id: CHEBI:17865
    label: Alpha-ketoisocaproate (KIC)
  - id: HP:0003811
    label: Neonatal death
  - id: HP:0001873
    label: thrombocytopenia
  - id: HP:0002615
    label: hypotension
  - id: HP:0002901
    label: hypocalcemia
  - id: HP:0001942
    label: metabolic acidosis
  - id: CHEBI:145810
    label: Insulin
  - id: MONDO:0008867
    label: biliary atresia
  - id: CHEBI:48430
    label: Alpha-ketoisocaproic acid (KIC)
  - id: MAXO:0000600
    label: renal replacement therapy (RRT)
  - id: MAXO:0000601
    label: dialysis
  - id: CHEBI:15603
    label: amino-acid mixture without leucine (Leu), valine, isoleucine
  - id: MAXO:0001495
    label: parenteral administration
  - id: MAXO:0000943
    label: Dried blood spot (DBS) monitoring
  - id: CHEBI:22918
    label: Branched-chain amino acids (BCAA)
  - id: CHEBI:33349
    label: <Dried blood spot (DBS)>
  - id: MONDO:0009949
    label: PC deficiency
  - id: HP:0001977
    label: abnormal blood clotting
  - id: HP:0000717
    label: Autism
  - id: HP:0001249
    label: Intellectual disability
  - id: HP:0001250
    label: Seizures
  - id: MONDO:0004739
    label: <Urea cycle defects (UCD), organic acidemias (OA), maple syrup urine disease
      (MSUD)>
  - id: HP:0001987
    label: elevated ammonia levels
  - id: CHEBI:29987
    label: Glutamate
  - id: CHEBI:21547
    label: N-acetylaspartate (NAA)
  - id: CHEBI:16919
    label: Creatine
  - id: HP:0006846
    label: acute encephalopathy
  - id: HP:0033667
    label: mental impairment (IQ <= 70)
  - id: HP:0001943
    label: Hypoglycemia
  - id: HP:0001257
    label: Spasticity
  - id: HP:0000988
    label: Rash
  - id: HP:0001876
    label: Pancytopenia
  - id: HP:0001919
    label: Acute kidney injury
  - id: HP:0030005
    label: Capillary leak syndrome
  - id: CHEBI:176838
    label: Riboflavin (vitamin B2)
  - id: CHEBI:176841
    label: Biotin (vitamin B7)
  - id: HP:0002878
    label: respiratory failure
  - id: HP:0010911
    label: Hyperleucinemia
  - id: MAXO:0001001
    label: gene therapy
  - id: HP:0000938
    label: osteopenia
  - id: CHEBI:28938
    label: ammonia
  - id: CHEBI:30860
    label: methylmalonic acid
  - id: CHEBI:15702
    label: Tissue plasminogen activator (tPA)
  - id: HP:0001699
    label: sudden death
  - id: MAXO:0000932
    label: Electroencephalography
  - id: HP:0001298
    label: Encephalopathy
  - id: HP:0002586
    label: peritonitis
  - id: HP:0003774
    label: chronic renal failure
  - id: MONDO:0008723
    label: Very-long chain acyl-CoA dehydrogenase deficiency (VLCAD)
